pharmaphorum

OCTOBER 7, 2022

Hence the decision to compare the HMTM group to their pre-study measures of cognition – including the ADAS-cog and ADCS-ADL scales – as well as to historical controls. points on ADAS-cog and 1 point for ADCS-ADL – whereas a typical Alzheimer’s patient would see a 5-point decline over that period.

FDA 85

FDA Immunization 85

pharmaphorum

DECEMBER 2, 2022

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its phase 3 confirmatory Clarity AD study for early Alzheimer’s disease and published them in the New England Journal of Medicine (NEJM).

59

59

STAT

JUNE 25, 2023

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference. Read the rest…

138

138

pharmaphorum

MAY 23, 2022

Orchard Therapeutics’ Strimvelis for the vanishingly rare “bubble boy” disease adenosine deaminase deficiency (ADA-SCID) – originally developed by GlaxoSmithKline – reached the market in 2016, but is still only available through a single clinic in Italy and is used in too few patients to cover its costs.

86

86

European Pharmaceutical Review

SEPTEMBER 22, 2023

These mAb treatments are further complicated by anti-drug antibody (ADA) responses in patients. 3 This high level of ADA induction may explain the reductions in treatment effects, despite high injected doses of the antibody. 2023 AD/PD Conference. 2022 Alzheimer’s Association International Conference.

Immunization 77

Immunization Vaccines Communication Labelling 77